Eric Stangeland

Vice President, Head of Discovery Sciences

At Valo, Eric leads the Discovery Sciences group consisting of an integrated team of medicinal and high throughput chemistry, DNA-encoded library chemistry and selections, analytical chemistry, ADME screening, protein sciences and in vitro pharmacology, and high throughput screening. Eric and his team utilize the proprietary computational modeling at Valo in combination with the company’s extensive laboratory capabilities to initiate and advance drug discovery programs with the Opal Computational Platform™️. Previously, he was Head of Medicinal Chemistry at Valo after joining in 2019 with the acquisition of Numerate, where he was Vice President of Medicinal Chemistry.

Eric has extensive experience in drug discovery and has led multiple programs across cardiovascular, pain, neurological, oncology, respiratory, anti-viral, and metabolic therapeutic areas. He has delivered eight development candidates and one compound to the market to date. Eric is an inventor on over 30 patents and an author on roughly 20 peer-reviewed articles or presentations at scientific meetings. Eric has a Ph.D. in Synthetic Organic Chemistry from the University of Colorado, Boulder.